Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration for the Treatment of Hyperglycemia in Metformin Monotherapy Treated Type 2 Diabetic Patients: a Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study.
Phase of Trial: Phase II/III
Latest Information Update: 15 Jun 2018
At a glance
- Drugs Canakinumab (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Registrational; Therapeutic Use
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 15 Mar 2012 This trial is discontinued in Great Britain, Hungary, Germany and has completed in Belgium.
- 17 Feb 2012 Actual patient number (556) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History